Science Corporation, the neurotechnology startup founded by former Neuralink president Max Hodak, says it has implanted its vision-restoring retinal chip in a patient with Stargardt disease for the first time, extending a device that had previously been tested primarily in people who lost sight to age-related macular degeneration.
The milestone marks a notable expansion of the company’s ambitions. Until now, the central proving ground for its subretinal implant has been geographic atrophy, the advanced “dry” form of age-related macular degeneration that erodes the light-sensing cells at the center of the retina and leaves patients with a blind spot where their sharpest vision used to be. Stargardt disease causes a similar kind of central vision loss, but through a very different route: it is an inherited condition, typically diagnosed in childhood or early adulthood, and it has no approved treatment.
How the implant works
Science Corporation’s approach sidesteps the damaged photoreceptors rather than trying to repair them. A thin chip is placed underneath the retina, in the region where the light-sensing cells have died off. Patients wear a pair of camera-equipped glasses that capture the scene in front of them and project a processed version of that image onto the chip. The implant converts the incoming light into small electrical pulses that stimulate the retinal cells still intact beneath the surface, which then pass signals along the optic nerve to the brain.
The result is not a restoration of natural eyesight. Vision delivered this way tends to be coarse and, at least initially, monochrome, and patients generally need a period of training to learn how to interpret what they are seeing. Still, for people who have lost the ability to read, recognize faces, or make out detail at the center of their visual field, regaining even a rough form of form vision can be meaningful.
Why Stargardt matters
Stargardt disease affects a far smaller population than macular degeneration, but it is a particularly compelling target for an implant like this. Because the condition strikes early in life, patients often live for decades with substantial central vision loss. And because the damage is concentrated in the macula while the rest of the retina’s circuitry typically remains functional, the underlying biology is broadly compatible with the way the chip is designed to work.
There is also a practical argument. Younger patients may adapt more readily to the demands of learning to use a prosthetic visual signal, which requires sustained practice with the glasses and the processing software that sits between the camera and the chip.
What comes next
A single implant is a starting point, not a verdict. The important questions now are how much usable vision the patient recovers, how stable the device proves over time, and whether results in Stargardt patients resemble those seen in the macular degeneration cohort. Those answers will take months of follow-up, and regulators will want data from more than one person before the technology could reach a broader population.
Science Corporation has been one of the more closely watched companies in the neural interface field, in part because it has pursued a visible, near-term clinical application rather than a speculative one. Restoring some measure of sight to people with untreatable retinal disease is a concrete goal with a clear benchmark for success, and expanding into Stargardt suggests the company believes its platform can generalize across the causes of central vision loss rather than serving a single diagnosis. Read More
Leave a Reply